Skip to content

Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System

Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04645641
Enrollment
150
Registered
2020-11-27
Start date
2020-10-12
Completion date
2020-12-31
Last updated
2020-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System

Detailed description

The objective of the study is to establish performance of the Dexcom CGM System (System) in comparison to a blood glucose comparator method.

Interventions

DEVICEContinuous Glucose Monitoring System

Continuous Glucose Monitoring System

Sponsors

DexCom, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Masking description

All systems worn will be blinded. Sensor wear locations will be pre-assigned. All sensor insertions will be performed at the clinic by study staff.

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ages 2 or older * Diagnosis of Type 1 diabetes or Type 2 diabetes * Willing to wear the required number of Systems for the total duration of study wear * Willing to participate in Clinic Session(s) during study wear

Exclusion criteria

* Presence of extensive skin changes/diseases at sensor wear site(s) that preclude wearing the sensor(s) on skin * Known allergy to medical-grade adhesives * Pregnancy * Hematocrit outside specification * ≥ 18 years of age: * Male: 36.0%; * Female: 33.0%; * 13-17 years of age: 35.0%; * 7 years - 12 years of age: 32.0%; * End stage renal disease and currently managed by dialysis or anticipating initiating dialysis during the study wear period * Required or scheduled to have a Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, or diathermy during the study wear period

Design outcomes

Primary

MeasureTime frameDescription
System Performance10 daysSystem Performance will be characterized with respect to comparator venous plasma measurements.

Secondary

MeasureTime frameDescription
System Related Adverse Device Effects10 daysSystem will be characterized by Adverse Device Effects experienced by study participants

Countries

United States

Contacts

Primary ContactStayce Beck, PhD, MPH
stayce.beck@dexcom.com858-203-6454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026